Trial · NCT03446612
Outcomes53
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 53
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in FBF Ratio in Response to Acetylcholine (Day 1 to Day 42) | Day 1 to Day 42 | Pharmacodynamic Per-Protocol (PDPP) population included all randomized participants who provided pharmacodynamic (PD) data at Day 1 and Day 42. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Ratio | MEAN |
| SECONDARY | Change in the Absolute FBF From Day 1 to Day 42 in Response to Acetylcholine | Day 1 to Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | ug/min | MEAN |
| SECONDARY | Change in FBF Ratio in Response to Sodium Nitroprusside (Day 1 to Day 42) | Day 1 to Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | Ratio | MEAN |
| SECONDARY | Change in the Absolute FBF From Day 1 to Day 42 in Response to Sodium Nitroprusside | Day 1 to Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | ug/min | MEAN |
| SECONDARY | Change in FBF Ratio in Response to NG-monomethyl Arginine Acetate (L-NMMA) (Day 1 to Day 42) | Day 1 to Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | Ratio | MEAN |
| SECONDARY | Change in the Absolute FBF From Day 1 to Day 42 in Response to L-NMMA | Day 1 to Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | umol/min | MEAN |
| SECONDARY | Change in FBF Ratio in Response to Acetylcholine at Day 42 Versus (vs) Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | Ratio | MEAN |
| SECONDARY | Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | Ratio | MEAN |
| SECONDARY | Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | Ratio | MEAN |
| SECONDARY | Change in FBF Ratio in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population | Ratio | MEAN |
| SECONDARY | Change in FBF Ratio in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population. | Ratio | MEAN |
| SECONDARY | Change in FBF Ratio in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | Ratio | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in the category titles). | ug/min | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | ug/min | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Daprodustat | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | umol/min | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to Acetylcholine at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population | ug/min | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to Sodium Nitroprusside at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population | ug/min | MEAN |
| SECONDARY | Change in the Absolute FBF in Response to L-NMMA at Day 42 vs Day 1 in Participants Treated With Darbepoetin Alfa | Day 1 and Day 42 | PDPP Population. Only those participants with data available at the specified data points were analyzed. | umol/min | MEAN |
| SECONDARY | Change in Augmentation Index (AIx) From Day 1 to 42 | Day 1 to Day 42 | PDPP Population | Percentage | MEAN |
| SECONDARY | Change in Pulse Wave Velocity (PWV) From Day 1 to Day 42 | Day 1 to Day 42 | PDPP Population | meters per second (m/sec) | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03446612/outcomes